Selected research
Industry Growth & Trends
Global Glutamate Receptor Ionotropic NMDA 2B Industry Growth and Trends Forecast to 2032
Market perspective
The global Glutamate Receptor Ionotropic NMDA 2B market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Glutamate Receptor Ionotropic NMDA 2B is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Glutamate Receptor Ionotropic NMDA 2B is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Glutamate Receptor Ionotropic NMDA 2B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Glutamate Receptor Ionotropic NMDA 2B include Johnson & Johnson, Novartis AG, UCB S.A., NeurOp, Inc, Luc Therapeutics, Inc., Cerecor Inc., Bristol-Myers Squibb Company and BioCrea GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Glutamate Receptor Ionotropic NMDA 2B market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Glutamate Receptor Ionotropic NMDA 2B market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Glutamate Receptor Ionotropic NMDA 2B market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Glutamate Receptor Ionotropic NMDA 2B.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Glutamate Receptor Ionotropic NMDA 2B market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Glutamate Receptor Ionotropic NMDA 2B Market by Company
Johnson & Johnson
Novartis AG
UCB S.A.
NeurOp, Inc
Luc Therapeutics, Inc.
Cerecor Inc.
Bristol-Myers Squibb Company
BioCrea GmbH
Glutamate Receptor Ionotropic NMDA 2B Segment by Type
JNJ-0808
Radiprodil
NP-11948
NP-10679
Neu-2000
Others
Glutamate Receptor Ionotropic NMDA 2B Segment by Application
Burns
Acute Ischemic Stroke
Brain Ischemia
Autism
Others
Glutamate Receptor Ionotropic NMDA 2B Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glutamate Receptor Ionotropic NMDA 2B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glutamate Receptor Ionotropic NMDA 2B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glutamate Receptor Ionotropic NMDA 2B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glutamate Receptor Ionotropic NMDA 2B manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Glutamate Receptor Ionotropic NMDA 2B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- JNJ-0808
- Radiprodil
- NP-11948
- NP-10679
- Neu-2000
- Others
Applications
- Burns
- Acute Ischemic Stroke
- Brain Ischemia
- Autism
- Others
Companies covered
- Johnson & Johnson
- Novartis AG
- UCB S.A.
- NeurOp, Inc
- Luc Therapeutics, Inc.
- Cerecor Inc.
- Bristol-Myers Squibb Company
- BioCrea GmbH
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales Estimates and Forecasts (2021-2032)
- 1.3 Glutamate Receptor Ionotropic NMDA 2B Market by Type
- 1.3.1 JNJ-0808
- 1.3.2 Radiprodil
- 1.3.3 NP-11948
- 1.3.4 NP-10679
- 1.3.5 Neu-2000
- 1.3.6 Others
- 1.4 Global Glutamate Receptor Ionotropic NMDA 2B Market Size by Type
- 1.4.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Size Overview by Type (2021-2032)
- 1.4.2 Global Glutamate Receptor Ionotropic NMDA 2B Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Glutamate Receptor Ionotropic NMDA 2B Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Glutamate Receptor Ionotropic NMDA 2B Industry Trends
- 2.2 Glutamate Receptor Ionotropic NMDA 2B Industry Drivers
- 2.3 Glutamate Receptor Ionotropic NMDA 2B Industry Opportunities and Challenges
- 2.4 Glutamate Receptor Ionotropic NMDA 2B Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Glutamate Receptor Ionotropic NMDA 2B Revenue (2021-2026)
- 3.2 Global Top Players by Glutamate Receptor Ionotropic NMDA 2B Sales (2021-2026)
- 3.3 Global Top Players by Glutamate Receptor Ionotropic NMDA 2B Price (2021-2026)
- 3.4 Global Glutamate Receptor Ionotropic NMDA 2B Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Glutamate Receptor Ionotropic NMDA 2B Major Company Production Sites & Headquarters
- 3.6 Global Glutamate Receptor Ionotropic NMDA 2B Company, Product Type & Application
- 3.7 Global Glutamate Receptor Ionotropic NMDA 2B Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Glutamate Receptor Ionotropic NMDA 2B Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Glutamate Receptor Ionotropic NMDA 2B Players Market Share by Revenue in 2025
- 3.8.3 2025 Glutamate Receptor Ionotropic NMDA 2B Tier 1, Tier 2, and Tier 3
4 Glutamate Receptor Ionotropic NMDA 2B Regional Status and Outlook
- 4.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Glutamate Receptor Ionotropic NMDA 2B Historic Market Size by Region
- 4.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales in Volume by Region (2021-2026)
- 4.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales in Value by Region (2021-2026)
- 4.2.3 Global Glutamate Receptor Ionotropic NMDA 2B Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Glutamate Receptor Ionotropic NMDA 2B Forecasted Market Size by Region
- 4.3.1 Global Glutamate Receptor Ionotropic NMDA 2B Sales in Volume by Region (2027-2032)
- 4.3.2 Global Glutamate Receptor Ionotropic NMDA 2B Sales in Value by Region (2027-2032)
- 4.3.3 Global Glutamate Receptor Ionotropic NMDA 2B Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Glutamate Receptor Ionotropic NMDA 2B by Application
- 5.1 Glutamate Receptor Ionotropic NMDA 2B Market by Application
- 5.1.1 Burns
- 5.1.2 Acute Ischemic Stroke
- 5.1.3 Brain Ischemia
- 5.1.4 Autism
- 5.1.5 Others
- 5.2 Global Glutamate Receptor Ionotropic NMDA 2B Market Size by Application
- 5.2.1 Global Glutamate Receptor Ionotropic NMDA 2B Market Size Overview by Application (2021-2032)
- 5.2.2 Global Glutamate Receptor Ionotropic NMDA 2B Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Glutamate Receptor Ionotropic NMDA 2B Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Johnson & Johnson Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Novartis AG Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 UCB S.A.
- 6.3.1 UCB S.A. Company Information
- 6.3.2 UCB S.A. Business Overview
- 6.3.3 UCB S.A. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 UCB S.A. Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.3.5 UCB S.A. Recent Developments
- 6.4 NeurOp, Inc
- 6.4.1 NeurOp, Inc Company Information
- 6.4.2 NeurOp, Inc Business Overview
- 6.4.3 NeurOp, Inc Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 NeurOp, Inc Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.4.5 NeurOp, Inc Recent Developments
- 6.5 Luc Therapeutics, Inc.
- 6.5.1 Luc Therapeutics, Inc. Company Information
- 6.5.2 Luc Therapeutics, Inc. Business Overview
- 6.5.3 Luc Therapeutics, Inc. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Luc Therapeutics, Inc. Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.5.5 Luc Therapeutics, Inc. Recent Developments
- 6.6 Cerecor Inc.
- 6.6.1 Cerecor Inc. Company Information
- 6.6.2 Cerecor Inc. Business Overview
- 6.6.3 Cerecor Inc. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Cerecor Inc. Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.6.5 Cerecor Inc. Recent Developments
- 6.7 Bristol-Myers Squibb Company
- 6.7.1 Bristol-Myers Squibb Company Company Information
- 6.7.2 Bristol-Myers Squibb Company Business Overview
- 6.7.3 Bristol-Myers Squibb Company Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Bristol-Myers Squibb Company Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.7.5 Bristol-Myers Squibb Company Recent Developments
- 6.8 BioCrea GmbH
- 6.8.1 BioCrea GmbH Company Information
- 6.8.2 BioCrea GmbH Business Overview
- 6.8.3 BioCrea GmbH Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 BioCrea GmbH Glutamate Receptor Ionotropic NMDA 2B Product Portfolio
- 6.8.5 BioCrea GmbH Recent Developments
7 North America by Country
- 7.1 North America Glutamate Receptor Ionotropic NMDA 2B Sales by Country
- 7.1.1 North America Glutamate Receptor Ionotropic NMDA 2B Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2026)
- 7.1.3 North America Glutamate Receptor Ionotropic NMDA 2B Sales Forecast by Country (2027-2032)
- 7.2 North America Glutamate Receptor Ionotropic NMDA 2B Market Size by Country
- 7.2.1 North America Glutamate Receptor Ionotropic NMDA 2B Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Glutamate Receptor Ionotropic NMDA 2B Market Size by Country (2021-2026)
- 7.2.3 North America Glutamate Receptor Ionotropic NMDA 2B Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Glutamate Receptor Ionotropic NMDA 2B Sales by Country
- 8.1.1 Europe Glutamate Receptor Ionotropic NMDA 2B Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2026)
- 8.1.3 Europe Glutamate Receptor Ionotropic NMDA 2B Sales Forecast by Country (2027-2032)
- 8.2 Europe Glutamate Receptor Ionotropic NMDA 2B Market Size by Country
- 8.2.1 Europe Glutamate Receptor Ionotropic NMDA 2B Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Glutamate Receptor Ionotropic NMDA 2B Market Size by Country (2021-2026)
- 8.2.3 Europe Glutamate Receptor Ionotropic NMDA 2B Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Sales by Country
- 9.1.1 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size by Country
- 9.2.1 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Glutamate Receptor Ionotropic NMDA 2B Sales by Country
- 10.1.1 South America Glutamate Receptor Ionotropic NMDA 2B Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2026)
- 10.1.3 South America Glutamate Receptor Ionotropic NMDA 2B Sales Forecast by Country (2027-2032)
- 10.2 South America Glutamate Receptor Ionotropic NMDA 2B Market Size by Country
- 10.2.1 South America Glutamate Receptor Ionotropic NMDA 2B Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Glutamate Receptor Ionotropic NMDA 2B Market Size by Country (2021-2026)
- 10.2.3 South America Glutamate Receptor Ionotropic NMDA 2B Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales by Country
- 11.1.1 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Market Size by Country
- 11.2.1 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Glutamate Receptor Ionotropic NMDA 2B Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Glutamate Receptor Ionotropic NMDA 2B Value Chain Analysis
- 12.1.1 Glutamate Receptor Ionotropic NMDA 2B Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Glutamate Receptor Ionotropic NMDA 2B Production Mode & Process
- 12.2 Glutamate Receptor Ionotropic NMDA 2B Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Glutamate Receptor Ionotropic NMDA 2B Distributors
- 12.2.3 Glutamate Receptor Ionotropic NMDA 2B Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst